{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:48:03Z","timestamp":1794952083975,"version":"4.9.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The optimal anticoagulant strategy for portal vein thrombosis (PVT) in patients with cirrhosis remains uncertain, particularly regarding the role of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs), low-molecular-weight heparin, or no anticoagulation. We conducted a systematic review and meta-analysis of studies evaluating DOAC therapy in patients with cirrhosis with PVT. Random-effects models were used to estimate pooled risk ratios (RRs). A total of 21 studies including 21\u2009506 patients with cirrhosis with PVT were analyzed. Among them, 2099 patients were treated with DOACs. Compared with VKAs, DOAC therapy was associated with higher rates of complete PVT recanalization (RR, 3.49; 95% confidence interval [CI], 2.06-5.93) and lower risk of PVT progression (RR, 0.19; 95% CI, 0.04-0.78), with no significant difference in major bleeding (RR, 1.09; 95% CI, 0.79-1.51). DOACs were also associated with a lower risk of intracranial hemorrhage (ICH; RR, 0.49; 95% CI, 0.30-0.80). Compared with no anticoagulation, DOAC therapy was associated with lower mortality (RR, 0.77; 95% CI, 0.71-0.84) without increased bleeding risk. DOAC benefit on recanalization was more pronounced in studies including only patients with Child-Pugh class A or B, whereas safety outcomes remained consistent across cirrhosis severity strata. In patients with cirrhosis with PVT, DOAC therapy is associated with improved complete recanalization and reduced PVT progression compared with VKAs, without increased bleeding risk and with lower risk of ICH. These findings support the use of DOACs in select patients, although randomized trials are needed to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019823","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:06:30Z","timestamp":1776276390000},"page":"4399-4411","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Direct oral anticoagulants in portal vein thrombosis in patients with cirrhosis: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9303-7790","authenticated-orcid":false,"given":"Andrea","family":"Boccatonda","sequence":"first","affiliation":[{"name":"1Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2809-1658","authenticated-orcid":false,"given":"Alice","family":"Brighenti","sequence":"additional","affiliation":[{"name":"1Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8429-1751","authenticated-orcid":false,"given":"Chiara","family":"Simion","sequence":"additional","affiliation":[{"name":"2Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Napolitano","sequence":"additional","affiliation":[{"name":"2Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5555-0745","authenticated-orcid":false,"given":"Carla","family":"Serra","sequence":"additional","affiliation":[{"name":"1Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-383X","authenticated-orcid":false,"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[{"name":"2Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-3741","authenticated-orcid":false,"given":"Elena","family":"Campello","sequence":"additional","affiliation":[{"name":"2Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"9","key":"2026062308480964100_bib1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2468-1253(24)00155-9","article-title":"Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies","volume":"9","author":"Elkrief","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2026062308480964100_bib2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3390\/jcm13051517","article-title":"Portal vein thrombosis: state-of-the-art review","volume":"13","author":"Boccatonda","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"2026062308480964100_bib3","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"2026062308480964100_bib4","first-page":"473","article-title":"Platelet, antiplatelet therapy and metabolic dysfunction-associated steatotic liver disease: a narrative review","volume":"14","author":"Boccatonda","year":"2024","journal-title":"Life (Basel)"},{"issue":"1","key":"2026062308480964100_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"2026062308480964100_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA clinical practice update: coagulation in cirrhosis","volume":"157","author":"O'Leary","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"2026062308480964100_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.gastro.2024.10.038","article-title":"AGA clinical practice update on management of portal vein thrombosis in patients with cirrhosis: expert review","volume":"168","author":"Davis","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"2026062308480964100_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/10600280211025050","article-title":"Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study","volume":"56","author":"Coons","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2026062308480964100_bib9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/MEG.0000000000001958","article-title":"Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis","volume":"33","author":"Ilcewicz","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"2026062308480964100_bib10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/10600280211047433","article-title":"Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis","volume":"56","author":"Oldham","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2026062308480964100_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MCG.0000000000001713","article-title":"Anticoagulation in cirrhosis: evidence for the treatment of portal vein thrombosis and applications for prophylactic therapy","volume":"56","author":"Martens","year":"2022","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"2026062308480964100_bib12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/MEG.0000000000001846","article-title":"Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis","volume":"32","author":"Ai","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"2026062308480964100_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"issue":"10","key":"2026062308480964100_bib14","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1007\/s10620-020-06695-4","article-title":"Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis","volume":"66","author":"Naymagon","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026062308480964100_bib15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"2026062308480964100_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026062308480964100_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"issue":"13-14","key":"2026062308480964100_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00508-018-1351-y","article-title":"Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function","volume":"130","author":"Scheiner","year":"2018","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"2026062308480964100_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.14309\/ajg.0000000000001194","article-title":"Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: a prospective observational study","volume":"116","author":"Lv","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2026062308480964100_bib20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","article-title":"Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis","volume":"19","author":"Mort","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2026062308480964100_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12876-023-02960-8","article-title":"Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"2026062308480964100_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/MEG.0000000000002787","article-title":"A pilot study of safety and efficacy comparison of low molecular heparin calcium sequential oral anticoagulants in the treatment of cirrhotic portal vein thrombosis","volume":"36","author":"Zhang","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026062308480964100_bib23","doi-asserted-by":"crossref","first-page":"109103","DOI":"10.1016\/j.thromres.2024.109103","article-title":"Impact of anticoagulation therapy on outcomes in patients with cirrhosis and portal vein thrombosis: a large-scale retrospective cohort study","volume":"241","author":"Niu","year":"2024","journal-title":"Thromb Res"},{"issue":"1","key":"2026062308480964100_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12072-024-10734-x","article-title":"Treatment of portal vein thrombosis in cirrhosis is associated with no survival advantage: a retrospective controlled study","volume":"19","author":"Cheloff","year":"2025","journal-title":"Hepatol Int"},{"issue":"6","key":"2026062308480964100_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/apt.18474","article-title":"Experience with dabigatran on rate of portal vein thrombosis recanalization, disease progression and survival","volume":"61","author":"Premkumar","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"1201","key":"2026062308480964100_bib26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/postmj\/qgaf062","article-title":"Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study","volume":"101","author":"Niu","year":"2025","journal-title":"Postgrad Med J"},{"issue":"1","key":"2026062308480964100_bib27","doi-asserted-by":"crossref","first-page":"10784","DOI":"10.1038\/s41598-024-60235-y","article-title":"Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis","volume":"14","author":"Tadokoro","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"2026062308480964100_bib28","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"10","key":"2026062308480964100_bib29","first-page":"479","article-title":"Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis","volume":"37","author":"Jones","year":"2020","journal-title":"Fed Pract"},{"issue":"2","key":"2026062308480964100_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11239-019-02035-0","article-title":"Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes","volume":"50","author":"Davis","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"suppl 1","key":"2026062308480964100_bib31","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1182\/blood-2025-4897","article-title":"Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis: an analysis of real-world data","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"2026062308480964100_bib32","doi-asserted-by":"crossref","first-page":"10760296241303758","DOI":"10.1177\/10760296241303758","article-title":"Direct oral anticoagulants versus traditional anticoagulation in cirrhotic patients with portal vein thrombosis: updated systematic review","volume":"30","author":"Xiao","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"issue":"8","key":"2026062308480964100_bib33","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.jhepr.2024.101116","article-title":"Direct oral anticoagulants in cirrhosis: rationale and current evidence","volume":"6","author":"Pereira Portela","year":"2024","journal-title":"JHEP Rep"},{"key":"2026062308480964100_bib34","doi-asserted-by":"crossref","first-page":"1134801","DOI":"10.3389\/fmed.2023.1134801","article-title":"Portal vein thrombosis in cirrhosis: a literature review","volume":"10","author":"Prakash","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026062308480964100_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2024.04.002","article-title":"Apixaban for the treatment of acute splanchnic vein thrombosis: a pilot study","volume":"237","author":"Kim","year":"2024","journal-title":"Thromb Res"},{"issue":"1","key":"2026062308480964100_bib36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"2026062308480964100_bib37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","year":"2022","journal-title":"J Hepatol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4399\/2527856\/blooda_adv-2026-019823-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4399\/2527856\/blooda_adv-2026-019823-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:58:24Z","timestamp":1782219504000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/12\/4399\/567779\/Direct-oral-anticoagulants-in-portal-vein"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019823","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,23]]},"published":{"date-parts":[[2026,6,15]]}}}